MB
TARS icon

MPM BioImpact’s Tarsus Pharmaceuticals TARS Stock Holding History

MPM BioImpact’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.3M Sell
322,007
-7,743
-2% -$495K 1.24% 31
2026
Q1 		$23.1M Buy
329,750
+881
+0.3% +$61.6K 1.79% 25
2025
Q4 		$26.9M Sell
328,869
-12,627
-4% -$943K 3.08% 12
2025
Q3 		$20.3M Hold
341,496
– – 3.32% 10
2025
Q2 		$13.8M Buy
+341,496
New +$15.4M 2.4% 18

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MPM BioImpact's TARS Position: Q2 2026 in Review

MPM BioImpact reduced its Tarsus Pharmaceuticals (TARS) stake by 2.3% in Q2 2026, selling an estimated $495K and leaving 322,007 shares worth $20.3M. The position accounts for 1.24% of the portfolio, ranked #31.

MPM BioImpact first reported a position in TARS in Q2 2025 and has held it in 5 quarters since. The position peaked at $26.9M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • MPM BioImpact held 322,007 shares of Tarsus Pharmaceuticals worth $20.3M as of Q2 2026.
  • MPM BioImpact sold 7,743 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $495K.
  • Tarsus Pharmaceuticals made up 1.24% of MPM BioImpact's portfolio in Q2 2026, its #31 holding.
  • MPM BioImpact first reported a position in Tarsus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • MPM BioImpact's Tarsus Pharmaceuticals position peaked at $26.9M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.